Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries
ObjectivesThe aim of the study was to assess the reimbursement policy for orphan drugs (ODs) in selected European countries in relation to the availability and impact of clinical evidence, health technology assessment (HTA) procedures and reimbursement decision-making.Materials and MethodsA list of...
Saved in:
Main Authors: | Szczepan Jakubowski (Author), Przemysław Holko (Author), Rafał Nowak (Author), Marisa Warmuth (Author), Marc Dooms (Author), Outi Salminen (Author), Lucas Cortial (Author), Gisbert W. Selke (Author), Christina Georgi (Author), Einar Magnússon (Author), Salvatore Crisafulli (Author), Fons Strijbosch (Author), Tanja Mueller (Author), Eleanor Grieve (Author), Immaculada Danés (Author), Paweł Kawalec (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
by: Szczepan Jakubowski, et al.
Published: (2024) -
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
by: Ewa Stawowczyk, et al.
Published: (2019) -
Orphan drugs' clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
by: Hans-Georg Eichler, et al.
Published: (2023) -
Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
by: Krzysztof Piotr Malinowski, et al.
Published: (2019) -
Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
by: Krzysztof Piotr Malinowski, et al.
Published: (2018)